Literature DB >> 7061255

A comparative study of ependymomas by site of origin.

J E Marks, S J Adler.   

Abstract

Sixty-one patients with histologically proven ependymoma were irradiated between 1954 and 1976. Supra-and infratentorial tumors occurred more often in children and spinal cord--cauda equina tumors more often in adults. Local control was achieved in four of 20 supratentorial, 13 of 26 infratentorial, three of seven intramedullary spinal cord, and seven of eight cauda equina tumors. Improved local control of infratentorial tumors was noted for patients who received higher biologically effective doses of radiation but no dose-response for supratentorial, spinal cord or cauda equina tumors could be found. Five-year actuarial survival was 56% for all patients, 35% for supratentorial, 59% for infratentorial, 57% for spinal cord and 83% for cauda equina tumors. Spinal metastases were pathologically documented in 5 of 46 (11%) patients with ependymomas above the foramen magnum. They were clinically evident in two patients and most common in patients with infratentorial tumors whose spines had not been irradiated. One patient who was irradiated externally for cauda equina tumor developed radiation myelopathy 1-1/2 years later; three of eight patients who received intrathecal gold 198 developed myelopathy and/or cauda equina syndrome 3-1/2 to 17 years later.

Entities:  

Mesh:

Year:  1982        PMID: 7061255     DOI: 10.1016/0360-3016(82)90382-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  40 in total

Review 1.  Radiation therapy and the management of intramedullary spinal cord tumors.

Authors:  S R Isaacson
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Prognostic relevance of localization and grading in intracranial ependymomas of childhood.

Authors:  R I Ernestus; R Schröder; H Stützer; N Klug
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

3.  Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center.

Authors:  Serap Akyurek; Eric L Chang; Tse-Kuan Yu; Darrin Little; Pamela K Allen; Ian McCutcheon; Anita Mahajan; Moshe H Maor; Shiao Y Woo
Journal:  J Neurooncol       Date:  2006-04-29       Impact factor: 4.130

4.  Surgical outcome and prognostic factors of spinal intramedullary ependymomas in adults.

Authors:  Ung Kyu Chang; Woo Jin Choe; Sang Kee Chung; Chun Kee Chung; Hyun Jib Kim
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

5.  Fourth ventricle ependymomas. A study of 20 cases with survival analysis.

Authors:  L Ferrante; L Mastronardi; G Schettini; P Lunardi; A Fortuna
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

6.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas.

Authors:  Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

Review 7.  Ependymomas of the filum terminale in childhood: report of four cases and review of the literature.

Authors:  F M Gagliardi; L Cervoni; M Domenicucci; P Celli; M Salvati
Journal:  Childs Nerv Syst       Date:  1993-02       Impact factor: 1.475

8.  Ependymoma of the filum terminale: treatment and prognostic factors in a series of 28 cases.

Authors:  P Celli; L Cervoni; G Cantore
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

9.  Supratentorial ependymomas in childhood: clinicopathological findings and prognosis.

Authors:  R I Ernestus; O Wilcke; R Schröder
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

10.  Interstitial irradiation of a large, low grade ependymoma with stereotactically implanted iodine-125 seeds. Case report.

Authors:  J Voges; C Gaus; W Schlegel; O Pastyr; B Wowra; V Sturm
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.